nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.04.2016 | Image of the Month

⁶⁸Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma

verfasst von: Arun Sasikumar, Ajith Joy, Raviteja Nanabala, M. R. A. Pillai, Boben Thomas, K. R. Vikraman

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Excerpt

⁶⁸Ga-labelled prostate-specific membrane antigen (PSMA) is emerging as the tool with the most potential for imaging recurrent prostate cancer [1]. There have been a few reports of significant accumulation of the tracer in metastatic clear cell renal carcinoma [2] and metastatic breast cancer [3]. The expression of PSMA in tumour-associated vasculature of breast cancer and primary gliomas has been reported [4]. Similar to prostate cancer, ¹⁸F-FDG PET/CT is also not the best imaging option in primary hepatocellular carcinoma (HCC). The potential of ⁶⁸Ga-PSMA for imaging primary HCC is not yet documented. …

Afshar Oromieh A, Avtzi E, Giesel FL, HollandLetz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.PubMedCentralCrossRefPubMed

Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halaç M, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–2.CrossRefPubMed

Sathekge M, Modiselle M, Vorster M, Mokgoro N, Nyakale N, Mokaleng B, et al. 68Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2015;42:1482–3.CrossRefPubMed

Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, et al. Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int. 2014;14:26.PubMedCentralCrossRefPubMed

Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med. 2012;4:140ra86. doi:10.1126/scitranslmed.3003886.PubMedCentralPubMed

Titel: 68Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma
verfasst von: Arun Sasikumar
Ajith Joy
Raviteja Nanabala
M. R. A. Pillai
Boben Thomas
K. R. Vikraman
Publikationsdatum: 01.04.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3297-x

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

⁶⁸Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma

Excerpt

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Symptomatic versus asymptomatic knees after bilateral total knee arthroplasty: what is the difference in SPECT/CT?

The value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in asymptomatic examinees with unexplained elevated blood carcinoembryonic antigen levels

Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis

EANM Springer Prizes awarded at EANM’15 Hamburg

FDG PET/CT in cancer: comparison of actual use with literature-based recommendations

Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease